A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)
Condition: Non-valvular Atrial Fibrillation (NVAF) Intervention: Drug: Rivaroxaban (Xarelto,Bay 59-7939) Sponsors: Bayer; Janssen Research & Development, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials